

Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study



Brigitte Rack,¹ Peter A. Fasching,² Lothar Häberle,² Thomas Friedl,³ Mahdi Rezaei,⁴ Jörn Hilfrich,⁵ Hans Tesch,⁶ Georg Heinrich,⁷ Helmut Forstbauer,⁸ Julia Neugebauer,¹ Elisabeth Trapp,¹ Susanne Albrecht,³ Bernadette Jäger,³ Tanja Fehm,⁹ Volkmar Müller,¹⁰ Andreas Schneeweiss,¹¹ Klaus Friese,¹ Werner Lichtenegger,¹² Matthias W. Beckmann,² Wolfgang Janni³

¹ Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, Campus Innenstadt, Munich, Germany; ² Department of Obstetrics and Gynecology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-Nürnberg, Erlangen, Germany; ³ Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany; ⁴ Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; ⁵ Diakoniekrankenhaus Henriettenstiftung, Hannover, Germany; ⁶ Oncological Center, Bethanien-Hospital, Frankfurt am Main, Germany; ⁷ Gynecological Treatment Center, Fuerstenwalde, Germany; ⁸ Hematooncological Treatment Center, Troisdorf, Germany; ⁹ Department of Gynecology and Obstetrics, Heinrich-Heine-University, Duesseldorf, Germany; ¹⁰ Department of Gynecology and Obstetrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¹¹ National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; ¹² Charité University Hospital Campus Virchow, Berlin, Germany

Aim
The prognostic value of CTCs at primary diagnosis has recently been confirmed by the SUCCESS A study (Rack et al., JNCI 2014). Key questions on the role of adjuvant bisphosphonate treatment, including patient populations deriving benefit and optimal timing/scheduling of therapy are still controversial. Aim of this study was therefore to evaluate the predictive value of zoledronate acid treatment (for 5 years vs for 2 years) on the prevalence of CTCs at 5 years after primary diagnosis additionally to other well-known predictors.

Methods
The SUCCESS A trial is a large, randomized, open-label, 2x2 factorial design Phase III study in patients with high risk breast cancer (stage N1 or T2-T4 or grade 3 or age ≤ 35 or hormone-receptor negative). Patients were first randomized to adjuvant chemotherapy treatment with 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide (FEC) followed by either 3 cycles of Docetaxel or 3 cycles of Gemcitabine-Docetaxel. In addition, patients were randomized to 2 years vs. 5 years of zoledronate treatment. CTC status before and after chemotherapy, as well as 2 and 5 years after primary diagnosis was assessed using the FDA-approved CellSearch System (Veridex, USA), and CTC positivity was defined as ≥ 1 CTC.

Statistical Methods
The primary objective was to study the predictive value of zoledronate treatment (for 2 years vs. for 5 years) on the prevalence of CTCs at 5 years after primary diagnosis, additionally to well-known predictors. A multiple logistic regression model was fitted with CTC status at 5 years as binary outcome (0 CTCs, > 0 CTCs) and the following predictors: zoledronate treatment (categorical; 2 years vs. 5 years), age at diagnosis (continuous), BMI at diagnosis (continuous), tumour stage (ordinal; pT1, pT2, pT3, pT4), lymph node status (categorical; pN0 and pN+), ER, PR, and HER2neu (each categorical; negative vs. positive), tumour type (categorical; ductal, lobular, other), CTC status before chemotherapy (categorical; 0 CTCs, > 0 CTCs), adjuvant chemotherapy (categorical; FEC-Doc vs. FEC-DocG). The Wald test was performed for zoledronate treatment. A significant p-value would indicate that zoledronate treatment influences the prevalence of CTCs at 5 years after primary diagnosis in addition to the considered predictors. Furthermore, the regression model was used to estimate adjusted odds ratios (ORs), especially for zoledronate treatment. Patients with missing outcome and patients with missing CTC information at 5 years were excluded. Missing predictor values were imputed using single "best guesses" (median value of continuous predictors, the most common value of categorical or ordinal predictors) based on non-missing data across all subjects. Continuous predictors were used as natural cubic

spline functions to describe non-linear effect (Hastie and Tibshirani, 1995). The number of knots of each predictor was determined by first fitting several simple logistic regression models which differ from each other by the number of knots (from 0 to 4) and then choosing the number of knots which optimizes the Akaike information criterion (AIC).

A sensitivity analysis was performed with a reduced logistic regression model to address the problem of over- as well as underestimation of regression coefficients due to too many variables per outcome event (Harrell et al., 1984; Peduzzi et al., 1996) and related to this, the problem of overfitting. A backward stepwise variable selection procedure with AIC as stop criteria was carried out on the condition that zoledronate treatment was kept in each selection step resulting in a reduced logistic regression model with zoledronate treatment and "the most important" predictors of the full model. As above, the Wald test was performed and adjusted ORs were estimated. The performance of the logistic regression models was measured with the area under the receiver operator curve (AUC) and the Hosmer-Lemeshow χ^2 test, where frequencies of predicted events were compared with frequencies of observed events. A large p-value indicates a satisfactory calibration. Model building was evaluated by 10-fold cross-validation with 50 repetitions to measure the amount of over-fitting. For this purpose, the model building process (i.e., determination of degrees of freedom for continuous predictors, the estimation of regression coefficients, variable selections) was done on each training set resulting in a logistic regression model, which was used then to calculate the AUC on the corresponding validation data set. The average of all these AUCs was taken as evaluation measure. All of the tests were two-sided, and a P value of < 0.05 was regarded as statistically significant. Calculations were carried out using the R system for statistical computing (version 3.0.1; R Development Core Team, Vienna, Austria, 2013)

Results
Patient and tumour characteristics
Data on CTC status at 5 years after primary diagnosis were available for 728 (19.4%) out of 3754 randomized patients. 65 patients (8.9%) had CTCs at five years after diagnosis and 663 (91.1%) had no CTCs. 310 patients had been randomized to 2 years of zoledronate treatment and 418 patients had been randomized to 5 years of zoledronate treatment. 93.8% of all patients had complete observations in all patients and tumour characteristics but CTCs at 2 years after diagnosis which was not considered for statistical analyses. The percentage of missing values in each predictor variable was below 0.5% except for HER2neu (1.8%) and CTC before chemo therapy (4.4%). The missing values of predictor variables were imputed

as described above. 19.2% of all patients had no information about CTCs at 2 years after diagnosis. Patient and tumour characteristics according to CTC prevalence at 5 years after diagnosis are shown in Table 1.

Zoledronate acid treatment and prevalence of CTCs at 5 years
We could not show that the duration of zoledronate treatment (2 or 5 years) influenced the prevalence of CTCs at 5 years after diagnosis (p = 0.13, Wald test). The adjusted OR for 2 years vs 5 years of treatment was 0.65 (95% CI: 0.37 to 1.13). The ORs for the predictors of the full logistic regression analysis is shown in Table 2. The reduced logistic regression model confirmed the main analysis. The adjusted OR and the p-value of the Wald test were exactly the same as above. ORs are shown in Table 3

Model performance and evaluation
The full logistic regression model seemed to be bad calibrated, whereas the calibration of the reduced model seemed to be rather good. Both models seemed to be over-fitted to a certain degree, because the cross-validated AUCs are lower than the apparent AUCs on the original data.

Conclusions
We could not show an influence of zoledronate treatment duration on the prevalence of CTCs five years after primary diagnosis. Other trials in this setting might provide additional information on the predictive role of CTCs in the context of bisphosphonate treatment.

- References**
- Rack et al. (2014), Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 15:106(5).
 - Hastie T and Tibshirani R (1995), Generalized additive models for medical research, Stat Methods Med Res 4:187-196.
 - Harrell et al. (1984), Regression model strategies for improved prognostic prediction. Stat Med 3:143-152.
 - Peduzzi et al. (1996), A simulation study of the number of events per variable in logistic regression analyses, J Clin Epidemiology 49:1373-1379

Acknowledgements
This translational research part of the SUCCESS trial was supported by AstraZeneca, Chugai, Lilly, Novartis, Sanofi-Aventis and Veridex. We would like to thank all patients for participating at this study and donating their blood samples for research purposes.

Characteristic	No CTC Mean or N	No CTC SD or %	At least one CTC Mean or N	At least one CTC SD or %
Age (years)	52.9	10.2	54.4	10.4
BMI (kg/m ²)	26.1	4.8	26.1	4.4
Tumor Stage				
pT1	310	46.8	23	35.4
pT2	322	48.6	41	63.1
pT3	22	3.3	1	1.5
pT4	9	1.4	0	0.0
Grading				
G1	33	5.0	2	3.1
G2	341	51.4	27	41.5
G3	289	43.6	36	55.4
Nodal status				
pN+	450	67.9	47	72.3
pN0	213	32.1	18	27.7
Tumor type				
Ductal	546	82.4	54	83.1
Lobular	72	10.9	6	9.2
Other	45	6.8	5	7.7
ER				
Negative	348	29.9	32	35.4
Positive	465	70.1	42	64.6
PR				
Negative	256	38.6	21	32.3
Positive	407	61.4	44	67.7
HER2				
Negative	484	73.0	53	81.5
Positive	179	27.0	12	18.5
Adjuvant chemotherapy				
FEC-DocG	323	48.7	33	50.8
FEC-Doc	340	51.3	32	49.2
CTCs before chemo				
0	543	81.9	52	80.0
> 0	120	18.1	13	20.0
CTCs at 2 years				
0	450	84.0	41	75.9
> 0	86	16.0	13	24.1
Zoledronate treatment				
2 years	288	43.4	22	66.2
5 years	288	43.4	22	33.8

Predictor	OR
Age (years)	per unit increase 1.02 (0.99, 1.05)
BMI (kg/m ²)	per unit increase 0.98 (0.92, 1.04)
Lymph node status	pN0 vs pN+ 0.68 (0.36, 1.27)
Tumor type	other epithelial vs ductal 1.07 (0.40, 2.89)
ER	ER+ vs ER- 0.46 (0.21, 1.01)
PR	PR+ vs PR- 2.39 (1.09, 5.23)
HER2neu	positive vs negative 0.56 (0.28, 1.09)
Adjuvant chemotherapy	AB vs AA 0.95 (0.56, 1.60)
Tumor stage	per unit increase 1.19 (0.78, 1.81)
Grading	per unit increase 1.88 (1.10, 3.18)
CTCs before chemo	CTC > 0 vs CTC = 0 1.12 (0.58, 2.16)
Zoledronate treatment	2 years vs 5 years 0.65 (0.38, 1.12)




Figure 1: SUCCESS study design




Figure 2: CTC positive rate before and after chemotherapy as well as 2 and 5 years after primary diagnosis